Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib vs chlorambucil + rituximab in untreated CLL without del(17p)/TP53 mutation
CTR20200238Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of acalabrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by AstraZeneca. Started Nov 2020; status: completed.
02
Drugs
acalabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20200238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200238.